Fig. 4

UTX^−/− ECs-Exos promotes macrophage polarization in vitro. A Western blotting analysis of the iNOS (M1 marker) and Arg-1 (M2 marker) expression of LPS-stimulated macrophages after being treated with different concentrations of UTX^−/−-Exos. B Statistical analysis of the Arg-1 expression in A. ^&P < 0.05 vs. 0 μg/ml UTX^−/−-Exos, *P < 0.05 vs. 10 μg/ml UTX^−/−-Exos, ^$P < 0.05 vs. 25 μg/ml UTX^−/−-Exos, ^#P < 0.05 vs. 50 μg/ml UTX^−/−-Exos, ^nsP > 0.05 vs. 100 μg /ml UTX^−/−-Exos. C Statistical analysis of iNOS expression in A. D Immunofluorescent co-staining of the CD86 (M1)/CD206 (M2) (red) and F4/80⁺ macrophages (green) after being treated with Vehicle, UTX^f/f-Exos, and UTX^−/−-Exos. Scale bars, 20 μm. E Statistical analysis of the mean fluorescence intensity of CD86 in D. F Statistical analysis of the mean fluorescence intensity of CD206 in D. G–L qRT-PCR analysis of the mRNA expression of M1 markers (iNOS2, TNF-ɑ, and CD86) and M2 markers (Arginase-1, IL-10, and CD206) of LPS-stimulated macrophages after treated with Vehicle, UTX^f/f-Exos, and UTX^−/−-Exos. M Representative scatter plots of the percentage of macrophage phenotypes when exposed to the Vehicle, UTX^f/f-Exos, and UTX^−/−-Exos. Mature macrophages are defined as F4/80⁺CD11b⁺, M1 macrophages are defined as CD11c⁺CD206⁻, and M2 macrophages are defined as CD11c⁻CD206⁺. The numbers in the gates refer to the percentage of positive cells for each marker. ^nsP > 0.05, *P < 0.05, **P < 0.01, compared with corresponding control mice. n = 6/per group